KR20010075202A - 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제 - Google Patents

라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제 Download PDF

Info

Publication number
KR20010075202A
KR20010075202A KR1020017003499A KR20017003499A KR20010075202A KR 20010075202 A KR20010075202 A KR 20010075202A KR 1020017003499 A KR1020017003499 A KR 1020017003499A KR 20017003499 A KR20017003499 A KR 20017003499A KR 20010075202 A KR20010075202 A KR 20010075202A
Authority
KR
South Korea
Prior art keywords
amino
pharmaceutical formulation
pharmaceutically acceptable
formulation
hydroxymethyl
Prior art date
Application number
KR1020017003499A
Other languages
English (en)
Korean (ko)
Inventor
나다니엘 에이. 브라운
린 디. 콘드리
더글라스 프레이저 그레이
마크 루빈
Original Assignee
그레이엄 브레레톤, 레슬리 에드워즈
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그레이엄 브레레톤, 레슬리 에드워즈, 글락소 그룹 리미티드 filed Critical 그레이엄 브레레톤, 레슬리 에드워즈
Publication of KR20010075202A publication Critical patent/KR20010075202A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020017003499A 1998-09-18 1999-09-17 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제 KR20010075202A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9820417.5 1998-09-18
GBGB9820417.5A GB9820417D0 (en) 1998-09-18 1998-09-18 Antiviral combinations
PCT/EP1999/006885 WO2000016779A1 (fr) 1998-09-18 1999-09-17 Combinaisons antivirales contenant de la lamivudine et de l'abacavir

Publications (1)

Publication Number Publication Date
KR20010075202A true KR20010075202A (ko) 2001-08-09

Family

ID=10839131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017003499A KR20010075202A (ko) 1998-09-18 1999-09-17 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제

Country Status (7)

Country Link
EP (1) EP1113803A1 (fr)
JP (1) JP2002526449A (fr)
KR (1) KR20010075202A (fr)
CN (1) CN1317971A (fr)
AU (1) AU6085099A (fr)
GB (1) GB9820417D0 (fr)
WO (1) WO2000016779A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230698B1 (hu) 2000-02-29 2017-09-28 Bristol-Myers Squibb Holdings Ireland Alacsony dózisú entecavir formuláció és alkalmazása
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
PL373758A1 (en) * 2002-06-27 2005-09-05 Medivir Ab Synergistic interaction of abacavir and alovudine
WO2012062835A1 (fr) * 2010-11-12 2012-05-18 Glaxo Wellcome Manufacturing Pte Ltd Nouvelles compositions pharmaceutiques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
CO4970782A1 (es) * 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
WO2000016779A1 (fr) 2000-03-30
AU6085099A (en) 2000-04-10
JP2002526449A (ja) 2002-08-20
EP1113803A1 (fr) 2001-07-11
CN1317971A (zh) 2001-10-17
GB9820417D0 (en) 1998-11-11

Similar Documents

Publication Publication Date Title
CA2216634C (fr) Combinaisons synergiques de zidovudine, 1592u89 et 3tc ou ftc
EA025176B1 (ru) Комбинация для лечения вич-инфекции
KR100413312B1 (ko) 항바이러스 복합약제
KR20010075202A (ko) 라미부딘 및 아바카비르를 포함하는 항바이러스 약학 제제
US6432966B2 (en) Antiviral combinations
AU723877C (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
EP3720440A1 (fr) Traitement du vrs avec une association médicamenteuse
WO2000016754A2 (fr) Combinaisons antivirales
TWI230610B (en) Dosage kits and pharmaceutical compositions for treating HIV infections
WO2000018383A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
JP2001509786A (ja) Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、および／または１５９２ｕ８９を含んでなる組合わせ

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application